. Author manuscript; available in PMC: 2026 Jul 7.

Published in final edited form as: JCO Precis Oncol. 2026 Jun 17;10(6):e2500769. doi: 10.1200/PO-25-00769

TABLE 2.

Homologous Recombination Deficiency Assessment

Histology	BRCA1/2 PV	Biallelic/Monoallelic^d	Mutational Signature	LOH	LST	TAI	HRD-Sum	HR Profiler	R/NR^e
Miscellaneous neoplasm, NOS	BRCA1_p.K679*_0.4871^a	Biallelic	Other	2	25	14	41	0.00	R
Invasive breast carcinoma	BRCA1_p.L1086*_0.3634^a	Monoallelic	MMR	7	14	12	33	0.00	NE
Salivary gland cancer	BRCA1_p.L28Rfs*3_0.437^a	Monoallelic	Other	2	23	12	37	0.00	NR
Breast cancer, NOS	BRCA1_p.Q563*_0.5217^a	Monoallelic	BRCA1/2	1	19	12	32	0.00	NR
Adenocarcinoma—pancreas	BRCA2_p.K3326*_0.4615^b	Monoallelic	Other	4	22	7	33	0.00	NE
Squamous cell carcinoma—anus	BRCA2_p.Q1925*_0.3719^a	Monoallelic^d	Other	9	11	14	34	0.00	NR
Invasive breast carcinoma	BRCA1_p.E670*_0.2992^a	Monoallelic^d	POLE	8	8	8	24	0.04	NR
Adenocarcinoma—colon	BRCA2_p.S2219*_0.1089^a	Monoallelic^d	Other	14	24	33	71	0.07	NR
Adenocarcinoma—pancreas	BRCA2_p.K3326*_0.785^b	Biallelic	Other	9	25	16	50	0.12	NE
Invasive breast carcinoma	BRCA2_p.Q1507*_0.5593^a	Monoallelic^d	AID/APOBEC	14	23	11	48	0.32	NR
Melanoma	BRCA1_p.S713*_0.65^a	Biallelic	Other	12	19	25	56	0.54	NR
Ovarian epithelial cancer	BRCA1_p.N1355Kfs*10_0.9649^a	Biallelic	BRCA1/2	17	27	26	70	0.61	NR
Carcinoma, NOS	BRCA2_p.V1283Kfs*2_1^a	Biallelic	UV	15	18	16	49	0.82	NE
Invasive breast carcinoma	BRCA2_p.W1692Mfs*3_0.5^a	Biallelic	BRCA1/2	18	24	33	75	0.86	NR
Invasive breast carcinoma	BRCA1_p.E23Vfs*17_0.8144^c	Biallelic	BRCA1/2	16	27	33	76	0.90	NR
Gall bladder carcinoma (adeno)	BRCA2_p.I2449Dfs*2_0.7339^a	Biallelic	BRCA1/2	26	32	38	96	0.97	NR
Neuroendocrine cancer NOS	BRCA2_p.I1859Kfs*3_0.85^a	Biallelic	BRCA1/2	22	31	30	83	0.97	NR
Ovarian epithelial cancer	BRCA2_p.R3128*_0.6218^a	Biallelic	BRCA1/2	29	31	35	95	0.99	R
Invasive breast carcinoma	BRCA1_p.P1315Dfs*12_0.6986^a	Biallelic^d	BRCA1/2	23	31	33	87	0.99	NE
Fallopian tube carcinoma	BRCA1_p.Q1756Pfs*74_0.7093^c	Biallelic	BRCA1/2	31	32	34	97	0.99	R (PR)
Adenocarcinoma—pancreas	BRCA2_p.N588Kfs*26_0.4783^a	Biallelic^d	BRCA1/2	33	37	33	103	1.00	NR
Female reproductive system cancer NOS	BRCA1_p.E23Vfs*17_0.6996^b	Biallelic	BRCA1/2	19	30	33	82	1.00	R

Abbreviations: CR, complete response; HR, homologous recombination; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale transitions; NE, nonevaluable; NOS, not otherwise specified; NR, nonresponder; PD, progressive disease; PR, partial response; R, responder; SD, stable disease; TAI, telomeric allelic imbalance.

Mutation likely oncogenic.

Mutation likely neutral.

Mutation oncogenic.

Somatic mutation (germline if not indicated).

Clinical benefit status, defined as defined as R (CR + PR + SD >6 months) or NR (PD + SD <6 months).